Xalkori (crizotinib) vs Darvias (darinaparsin) ()

Xalkori (crizotinib) is an oral medication specifically approved for the treatment of non-small cell lung cancer (NSCLC) with specific genetic alterations, namely ALK or ROS1 rearrangements, and it works by inhibiting the activity of these cancer-driving proteins. Darvias (darinaparsin), on the other hand, is an investigational organic arsenic compound with potential antineoplastic activity, but it has not been approved by regulatory agencies like the FDA for any specific cancer treatment as of the knowledge cutoff date. When deciding between the two, a patient should consider the specific type of cancer they have, the genetic profile of their cancer if applicable, and should consult with their oncologist to determine the most appropriate therapy based on the current evidence and approval status of the medications.

Difference between Xalkori and Darvias (darinaparsin)

Metric	Xalkori (crizotinib)	Darvias (darinaparsin)
Generic name	Crizotinib	Darinaparsin
Indications	ALK or ROS1-positive non-small cell lung cancer (NSCLC)	Under investigation for various cancers including solid tumors and hematologic malignancies
Mechanism of action	ALK and ROS1 tyrosine kinase inhibitor	Organic arsenic compound that induces apoptosis and inhibits cell proliferation
Brand names	Xalkori	Darvias
Administrative route	Oral	Intravenous
Side effects	Visual disturbances, GI disturbances, edema, elevated liver enzymes, etc.	Nausea, vomiting, fatigue, abdominal pain, etc.
Contraindications	Hepatic impairment, concomitant use with strong CYP3A inhibitors/inducers	Severe renal impairment, hypersensitivity to arsenic
Drug class	Tyrosine kinase inhibitor	Organic arsenic
Manufacturer	Pfizer	ZIOPHARM Oncology

Efficacy

Xalkori (Crizotinib) and Its Efficacy in Lymphoma

Xalkori, known generically as crizotinib, is a medication primarily used to treat non-small cell lung cancer (NSCLC) that is caused by a defect in the ALK or ROS1 genes. However, its efficacy in lymphoma, particularly anaplastic large cell lymphoma (ALCL), which can express aberrations in the ALK gene, has been a subject of research. Studies have shown that crizotinib can be effective in treating ALK-positive ALCL, as the drug inhibits the activity of the ALK protein, which can drive the growth of these lymphoma cells. While the use of crizotinib in lymphoma is considered off-label, it represents a potential targeted therapy for patients with ALK-positive ALCL.

Despite the promise, the use of crizotinib in lymphoma is not as well-established as its use in NSCLC. Clinical trials and case reports have suggested that crizotinib may induce responses in ALK-positive lymphoma patients, but larger, controlled studies are needed to fully understand its efficacy and safety in this context. It is important for healthcare providers to consider the individual patient's condition and the existing evidence when considering crizotinib for lymphoma.

Darvias (Darinaparsin) and Its Efficacy in Lymphoma

Darvias, with the active ingredient darinaparsin, is a novel organic arsenic compound that has been investigated for its potential in treating various types of cancer, including lymphoma. Darinaparsin has demonstrated anticancer activity in preclinical studies by inducing apoptosis and inhibiting proliferation in malignant cells. In lymphoma, darinaparsin has been evaluated in clinical trials for its efficacy against different subtypes, including Hodgkin's lymphoma and non-Hodgkin's lymphoma.

Although darinaparsin is not yet widely used in clinical practice for lymphoma, early-phase clinical trials have shown that it can produce a clinical response in some patients with lymphoma. The drug's mechanism of action, involving oxidative stress induction and mitochondrial dysfunction in cancer cells, provides a rationale for its use in refractory or relapsed lymphoma cases. As with any investigational drug, the efficacy of darinaparsin in lymphoma must be further validated through larger-scale clinical trials to establish its role in the treatment of this disease.

Regulatory Agency Approvals

Xalkori

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia

Darvias (darinaparsin)

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Access Xalkori or Darvias (darinaparsin) today

If Xalkori or Darvias (darinaparsin) are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Xalkori

Buy Darvias (darinaparsin)

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: